According to a new analysis of patient claims data, “The Abortion Pill Harms Women,” by the Ethics and Public Policy Center (EPPC), the Food and Drug Administration (FDA) has severely underestimated the rate of serious adverse medical events after taking the abortion drug mifepristone. The incidence of serious adverse events is nearly 22 times the rate the FDA currently recognizes on the required drug label for the chemical abortion drug Mifeprex.
Now that chemical abortions make up approximately two-thirds of all abortions in the United States, women’s safety must be more a priority than ever. AUL is proud to release its comprehensive, state-by-state summary of statutory restrictions on chemical abortion in an effort to aid enforcement and further lawmaking to protect women from these dangerous drugs.
Stop-Harming-Women-Policy-Document
